Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Haluk Yuzugullu"'
Autor:
Gokhan Yildiz, Ayca Arslan-Ergul, Sevgi Bagislar, Ozlen Konu, Haluk Yuzugullu, Ozge Gursoy-Yuzugullu, Nuri Ozturk, Cigdem Ozen, Hilal Ozdag, Esra Erdal, Sedat Karademir, Ozgul Sagol, Dilsa Mizrak, Hakan Bozkaya, Hakki Gokhan Ilk, Ozlem Ilk, Biter Bilen, Rengul Cetin-Atalay, Nejat Akar, Mehmet Ozturk
Publikováno v:
PLoS ONE, Vol 8, Iss 5, p e64016 (2013)
Senescence is a permanent proliferation arrest in response to cell stress such as DNA damage. It contributes strongly to tissue aging and serves as a major barrier against tumor development. Most tumor cells are believed to bypass the senescence barr
Externí odkaz:
https://doaj.org/article/8e1281cde73745e7a1c2cc9e38f3e9db
Autor:
Mine Mumcuoglu, Sevgi Bagislar, Haluk Yuzugullu, Hani Alotaibi, Serif Senturk, Pelin Telkoparan, Bala Gur-Dedeoglu, Burcu Cingoz, Betul Bozkurt, Uygar H Tazebay, Isik G Yulug, K Can Akcali, Mehmet Ozturk
Publikováno v:
PLoS ONE, Vol 5, Iss 6, p e11288 (2010)
BACKGROUND: Breast cancer is a remarkably heterogeneous disease. Luminal, basal-like, "normal-like", and ERBB2+ subgroups were identified and were shown to have different prognoses. The mechanisms underlying this heterogeneity are poorly understood.
Externí odkaz:
https://doaj.org/article/2834daefa7c942d09e8c08fae1d66d1e
Autor:
Gökhan Karakülah, Ezgi Bagirsakci, Petek Ballar Kirmizibayrak, Hamdiye Uzuner, Peyda Korhan, Hani Alotaibi, Neşe Atabey, Mehmet Ozturk, Haluk Yuzugullu, Ozge Gursoy Yuzugullu, Cigdem Ozen, Funda Yilmaz, Umut Ekin
Publikováno v:
Journal of Gastrointestinal Cancer
Purpose Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related death worldwide with. lack of effective systemic chemotherapy. In this study, we aimed to evaluate the value of ATPase family AAA domain-containing protein 2 (ATAD2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e46b984f100deb4225c87bb13050ca3e
https://avesis.deu.edu.tr/publication/details/98399a58-bf14-4175-9659-b85933af8057/oai
https://avesis.deu.edu.tr/publication/details/98399a58-bf14-4175-9659-b85933af8057/oai
Autor:
April C. Watt, Sara M. Tolaney, X. Shirley Liu, Lyndsay Harris, Deborah A. Dillon, Ian E. Krop, Jean J. Zhao, Vinay Varadan, Wei Li, Adam C. Palmer, Susanne Ramm, Eric P. Winer, Qi Wang, Piotr Sicinski, Kwok-Kin Wong, David Tuck, Haluk Yuzugullu, Shom Goel
Publikováno v:
Cancer Cell. 29:255-269
Using transgenic mouse models, cell line-based functional studies, and clinical specimens, we show that cyclin D1/CDK4 mediate resistance to targeted therapy for HER2-positive breast cancer. This is overcome using CDK4/6 inhibitors. Inhibition of CDK
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a4f11e99c65c21b09b12366e0eb8fc69
https://doi.org/10.1016/j.ccell.2016.02.006
https://doi.org/10.1016/j.ccell.2016.02.006
Autor:
Howard Yan, Thomas M. Roberts, Christine Fritsch, Kira Gritsman, Gregory Hollingworth, Tulasi Khandan, Rachel Okabe, Christine Choi, Thanh Von, Mahnaz Paktinat, Haluk Yuzugullu, Linda K. Clayton, Sauveur Michel Maira, Jean J. Zhao
Publikováno v:
Journal of Clinical Investigation. 124:1794-1809
The genes encoding RAS family members are frequently mutated in juvenile myelomonocytic leukemia (JMML) and acute myeloid leukemia (AML). RAS proteins are difficult to target pharmacologically; therefore, targeting the downstream PI3K and RAF/MEK/ERK
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b981165f425570fcd63e50d72f587b82
https://doi.org/10.1172/jci69927
https://doi.org/10.1172/jci69927
Autor:
Eric M. Tam, Sara Ghassemifar, Lia Luus, Yasmin Hashambhoy-Ramsay, Andrew J. Sawyer, Haluk Yuzugullu, Daryl C. Drummond, Birgit Schoeberl, Tim Maiwald, Peter K. Sorger, Maja Razlog, Hannah Hudson, Tamara Utermark, Violette Paragas, C. Patrick Reynolds, Diane Chai
Publikováno v:
Cancer Research. 79:700-700
In colorectal cancer (CRC), RAS mutated cancers comprise 30-50%, for which there are limited treatment options. Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) has been found to selectively induce cell death in 50% of the CRC ce
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5575ea81de2d1baf293555a92c3249a2
https://doi.org/10.1158/1538-7445.am2019-700
https://doi.org/10.1158/1538-7445.am2019-700
Autor:
Haluk Yuzugullu, Ozge Gursoy-Yuzugullu
Publikováno v:
Liver Research - Open Journal. 1:e1-e3
Hepatocellular carcinoma (HCC), one of the most frequent neoplasms worldwide, causes more than 700,000 deaths per year, and is the third cause of cancer-related mortality. 1-3 HCC occurs after years of damage to hepatocytes with inflammatory conditio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0688d6fe7406a4d214e100aa61fdb475
https://doi.org/10.17140/lroj-1-e001
https://doi.org/10.17140/lroj-1-e001
Autor:
Sarah R. Walker, David A. Frank, Thomas M. Roberts, Jean J. Zhao, Haluk Yuzugullu, Thanh Von, Lauren M. Thorpe
Publikováno v:
Cell Discovery
Loss of PTEN, a negative regulator of the phosphoinositide 3-kinase signaling pathway, is a frequent event in T-cell acute lymphoblastic leukemia, suggesting the importance of phosphoinositide 3-kinase activity in this disease. Indeed, hyperactivatio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8e6a70ac459110db908bf1738b4fb305
https://doi.org/10.1038/celldisc.2016.30
https://doi.org/10.1038/celldisc.2016.30
Publikováno v:
Liver International. 31:561-571
Background: Hepatocellular carcinoma (HCC) is a leading cause of cancer deaths. Aflatoxins, which may play a causative role in 5‐28% of HCCs worldwide, are activated in liver cells and induce principally G ! T mutations, including the TP53 codon 24
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::98a1be2a0083d01e00432fcd56d3e10b
https://doi.org/10.1111/j.1478-3231.2011.02474.x
https://doi.org/10.1111/j.1478-3231.2011.02474.x
Autor:
Jing Ni, Thanh Von, Jean J. Zhao, Kira Gritsman, Haluk Yuzugullu, Roderick T. Bronson, Lukas Baitsch, Haoxuan Tong, Linda K. Clayton, Thomas M. Roberts, Allison Steiner
Publikováno v:
Nature Communications
The tumour suppressor PTEN, which antagonizes PI3K signalling, is frequently inactivated in haematologic malignancies. In mice, deletion of PTEN in haematopoietic stem cells (HSCs) causes perturbed haematopoiesis, myeloproliferative neoplasia (MPN) a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c3cafd8581eea8b319b590b5b28bce0
http://europepmc.org/articles/PMC4598950
http://europepmc.org/articles/PMC4598950